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Abstract
Background: Bacteriophages may induce specific antibodies after natural exposure to phages or after phage
therapy. As such, phage-specific antibodies might impact phage bioavailability in vivo, although limited non-
neutralizing or insignificant effects have also been reported.
Materials and Methods: Here, we report antibody induction against PB1-related phages (Pseudomonas viruses
LMA2, F8, DP1) in mice over an 80-day period, for a healthy population of humans, and in patients undergoing
phage therapy (oral and/or topical treatment).
Results: All phages effectively induced specific immunoglobulin M and immunoglobulin G in mice. Phage-
specific antibodies were observed in humans, whereas recombinant virion proteins (PB1 gp22, gp29) did not
induce phage-neutralizing antibodies, either in mice or in humans. The healthy human population was dif-
ferentiated for frequency of phage-neutralizing antibodies.
Conclusions: These data can hold key considerations for phage therapy cocktail design, as highly similar
phages can still be highly complementary in cases where specific immune response hinders therapeutic use of
phages.
Keywords: immune response, antibodies, PB1-related phages, phage therapy, virion proteins, Pseudomonas
aeruginosa PAO1
Introduction
Bacteriophages (phages) are capable of inducing aspecific antibody response, as demonstrated in animal
models1–7 and as observed in humans.6,8–10 Animals and hu-
mans are naturally exposed to phages when phages ubiqui-
tous in the environment and in natural microbiomes enter an
organism. In phage therapy this exposition is artificial, as
selected phages are given as therapeutic agents in high rela-
tive concentrations. Nevertheless, these phages from cock-
tails have also been selected from natural sources in the
environment. The multiplicity of similar phages and phage
groups that we are exposed to results in antibodies that may
show cross-reactions. The specific response induced by an
individual phage may affect another one, including both
therapeutic and natural phage isolates.
Phage-specific antibodies are typically expected to affect
pharmacokinetics and bioavailability of active phages in
animals and humans. However, examples of both exten-
sive11–13 and insignificant9,14–17 effects of specific antibodies
on phages have been reported. This makes it difficult to
predict phage bioavailability in the presence of specific an-
tibodies. Since phage-specific antibodies are, in fact, anti-
bodies specific to phage virions, that is, to many different
structural proteins, phage immunogenicity may differ de-
pending on the protein compositions of the phage capsids.6,7
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Accordingly, the immune response to a phage is rather a sum
of responses to different proteins of this phage. Further, as
postulated by Jerne and Avegno,18 and Jerne,19 only a frac-
tion of phage-specific antibodies can be neutralizing. Thus,
individual identification of immunogenic proteins in phage
virions, together with individual assessment of their ability
to induce phage-neutralizing antibodies seems to be crucial
for our understanding of how a particular phage (or a group
of phages) interacts with the immune system, and how the
response affects the phage.
Here, we present an analysis of antibody induction by three
very closely related phages from PB1-like genus (Pbuna-
virus): LMA2, DP1 (full name: vB_PaeM_CEB_DP1), and
F8 (or F-8). They are all active against Pseudomonas aeru-
ginosa and belong to the therapeutic set of phages (in case of
F8) used in the Phage Therapy Center, Hirszfeld Institute of
Immunology and Experimental Therapy, Wrocław, Poland
(PTU HIIET).20 As such, the analysis of antibodies specific
to these phages is relevant to the phage therapy cocktail
design for individual patient treatment.
Materials and Methods
Bacteriophages and bacterial host strain
Bacteriophage F8 (or F-8; NC_007810) was obtained from
the Polish Collection of Microorganisms at the Hirszfeld
Institute of Immunology and Experimental Therapy, Polish
Academy of Science (HIIET PAS). Bacteriophages LMA2
(NC_011166) and DP1 (NC_041870; full name: vB_PaeM_
CEB_DP1) were previously described.21,22 All three phages
were propagated on Pseudomonas aeruginosa PAO1 (DSM
22644).
Preparation of phage lysates
Flasks containing enriched nutrient broth were inoculated
with a 3-h culture of Pseudomonas aeruginosa PAO1.
Phages were added to the flasks to the final concentration of
8 · 108 pfu/mL, and the cultures were incubated at 37C with
vigorous shaking for 5 h. After that time, the flasks were kept
at 4C for 1 day to clarify. Phage lysates were then centri-
fuged at 8000 rpm. The supernatants were filtered through
0.22 lm membrane filters (Merck Millipore) and purified
by using size exclusion chromatography (gell filtration) on
Sepharose 4B using fast protein liquid chromatography
(FPLC) (Sigma-Aldrich); detailed information on timing and
absorbance is presented in Supplementary Figure S1. This
step was followed by dialysis through 1000 kDa membranes
(Spectrum Laboratories, USA) against phosphate-buffered
saline (PBS) (Na2HPO4 6.5 lM, KCl 3 mM, KH2PO4 1.5 mM,
NaCl 137 mM, Na2HPO4 · 12H2O 8.1 · M). Phage titers in
lysates and purified preparations were determined by using
serial dilutions, and the spot plating technique. Lipopoly-
saccharide (LPS) content was determined by using EndoLISA
(Hyglos GmbH, Germany) according to the manufacturer’s
instructions with minor modifications. Overnight incubation
at the first step was applied. Plate reader EnSpire Multilabel
Plate Reader Perkin Elmer was used. Detailed information
on phage titer, endotoxin concentration, and relevant chro-
matograms are presented in Supplementary Figure S1 and
Supplementary Table S1.
Phage proteins isolation and purification
Two sets of phage proteins were investigated in this study:
gp22 (encoded by ORF22 for phages F8 and LMA22, and
ORF23 for DP1) and gp29 (encoded by ORF29 for phages F8
and LMA22, and ORF30 for DP1); these proteins were putative
structural proteins of the phages based on similar phage anno-
tation. Due to inconsistencies in their names and numbers,
proteins investigated herein were designed as gp22 and gp29.
Their respective designations in the National Center for Bio-
technology Information (NCBI) database are as follows: in F8
phage ‘‘hypothetical protein ORF022’’ and ‘‘hypothetical pro-
tein ORF029,’’ in LMA2 phage ‘‘ORF22,’’ ‘‘putative structural
protein’’ and ‘‘ORF29,’’ ‘‘putative structural protein,’’ and in
DP1 phage ‘‘FDG87_gp24,’’ ‘‘putative structural protein’’ and
‘‘FDG87_gp31,’’ and ‘‘putative structural protein.’’
Protein-coding sequences were cloned by using Gateway
technology (Thermo Fisher) to pDEST24 vector allowing for
the expression of recombinant products with glutathione S-
transferase (GST) affinity tags and expressed in the Escherichia
coli expression system by using Escherichia coli B834(DE3) F-
ompT hsdSB(rB- mB-) gal dcm met (DE3) (Novagen). Bac-
teria were grown in lysogeny broth (LB) high salt (10 g/L of
NaCl) culture medium (Sigma-Aldrich) with ampicillin at 37C
overnight as a preculture; then, an expression culture was in-
oculated with 1 mL of preculture per 1 L of LB and it was cul-
tured with ampicillin at 37C to an optical density (OD600) of 0.8.
Next, isopropylthio-b-D-galactoside (Thermo Scientific)
was added to a final concentration of 0.2 or 0.8 mM (for gp22
and gp29, respectively) to induce expression of phage proteins.
Bacteria were further cultured overnight at 25C. and centri-
fuged for 5 min at 8000 rpm. The collected bacteria were
suspended in phosphate buffer (50 mM Na2HPO4, 300 mM
NaCl, pH 8.0), treated with phenylmethylsulfonyl fluoride
(1 mM), and incubated on ice for 15 min. Lysis was achieved
by incubation with lysozyme (0.5 mg/mL) for 5 h on ice and by
the freeze-thaw method (overnight at -80C). Subsequently,
the preparation was supplemented with Mg2+ (up to 0.5 mM),
DNase I (10 lg/mL), and RNase A (20 lg/mL), and it was
incubated on ice for 3–4 h. Fractions were separated by double
centrifugations (12,000 rpm, 45 min, 15C). The soluble frac-
tion was filtered through 0.45 lm polyvinylidene difluoride
(PVDF) filters (Millipore) and incubated with glutathione
sorbent slurry (Glutathione Sepharose 4B; GE Healthcare Life
Sciences, Poland).
The resin was subsequently washed with phosphate buffer,
and proteins were released by proteolysis with rTev protease
(5 U/mL) (Pure Biologics, Poland) at 10C; GST tags re-
mained bound in the resin. Protein preparations were puri-
fied: (1) initial LPS removal with EndoTrap HD (Hyglos
GmbH), (2) gel filtration FPLC on a Superdex 75 10/300 GL
column (GE Healthcare Life Sciences) for final separation of
proteins, and (3) a final step of LPS removal with EndoTrap
HD (Hyglos GmbH) followed by dialysis against PBS and
filtration through 0.22-lm (PVDF) filters. Protein purity was
inspected by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and concentrations were determined by us-
ing the Lowry chromogenic method (Thermo Scientific). The
resulting proteins were positively verified by reaction with
reference sera specific to whole phage virions. LPS content
was determined by using EndoLISA (Hyglos GmbH) ac-
cording to the manufacturer’s instructions.
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Murine protein-specific plasma
To obtain phage protein-specific plasma samples, C57BL/6J
male mice (Center of Experimental Medicine, Medical Uni-
versity of Bialystok) were administered three doses of
highly purified recombinant phage proteins intraperitone-
ally (IP) (200 lg/mouse each on days 0, 14, and 28). Blood
was collected from the orbital vein to heparinized tubes, and
plasma was separated by double centrifugation (2250 · g and
10,000 · g; 10 min each) and stored at -80C for further use.
Animal immunization model
C57BL/6J male mice (N = 7) (Center of Experimental
Medicine, Medical University of Bialystok) were adminis-
tered IP three doses of PBS (control group) or highly purified
phage preparations (F8, LMA2, DP1), at 1010 pfu per mouse
each on days 0, 20, and 55. Blood samples were collected
from the tail vein on days 1, 5, 10, 15, 20, 22, 25, 35, 40, 45,
50, 55, 60, 64, 70, 80; plasma was separated as described
earlier and stored at -20C for further use. Non-challenged
mice from the same batch were included in each experiment
to serve as the control for possible off-target antibodies in the
murine plasma.
Human samples
Human sera samples representing a healthy population
were collected from 55 healthy donors, both male and female
(age range: 18–40 years), who had never been subjected to
phage therapy or involved in phage work. Blood was col-
lected into heparinized tubes, and serum was separated
from the blood by double centrifugation at 2250 · g. The
same sera (stored in HIIET’s collection) were used as in
previous studies for T4 phage6 and A3R and 676Z phage
(Kaźmnierczak et al., manuscript under assessment).
Human sera of 11 patients undergoing phage therapy with
bacteriophage F8 were collected at the Phage Therapy Unit
of HIIET PAS. Blood samples were taken 1–5 days or just
before starting phage therapy and during/after the treat-
ment. The sera were separated from heparinized blood sam-
ples by centrifugation (10 min, 1500 · g) and stored at -70C
for further use.
All experiments were conducted in accordance with the
Declaration of Helsinki and approved by the local Commis-
sion of Bioethics, Wroclaw Medical University.
Specific antibody level measurement
by enzyme-linked immunosorbent assay
MaxiSorp flat-bottom 96-well plates (Nunc; Thermo Sci-
entific) were coated with 100 lL of highly purified proteins
(1 lg/well) or phage preparations (5 · 108 pfu/well), or with
albumin as the negative control, overnight at 4C. Irrelevant
serum was used as the specificity control. Since no universal
(for the three phages) standard serum was available, only
relative comparisons were applied. Plates were then washed
five times with PBS and blocked with 1% (w/v) albumin
(Sigma) in PBS at room temperature for 1 h. Blocking solu-
tion was then removed, and plates were washed five times
with PBS with 0.05% (v/v) Tween 20 (BD Biosciences).
Murine or human plasma samples diluted in PBS were then
added to wells in duplicate at 100 lL per well and incubated
at 37C for 2 h. Subsequently, plates were washed five times
with PBS with 0.05% (v/v) Tween 20, and 100 lL per well of
diluted horseradish peroxidase-conjugated detection anti-
body was added: goat anti-mouse immunoglobulin M (IgM)
( Jackson ImmunoResearch Laboratories), immunoglobulin
G (IgG) ( Jackson ImmunoResearch Laboratories), or goat
anti-human IgG (Abcam). Plates were incubated for 1 h at
room temperature in the dark and then again washed
five times with PBS with 0.05% (v/v) Tween 20. 3,3¢,5,5¢-
Tetramethylbenzidine (TMB) (50 lL/well) was used as a
substrate reagent for horseradish peroxidase (HRP) accord-
ing to the manufacturer’s instructions (R&D Systems) and
incubated for 30 min. Finally, 25 lL of 2N H2SO4 was added
to stop the reaction, and the absorbance was measured at
450 nm (main reading) and normalized by subtracting the
background absorbance at 570 nm.
Reverse cumulative distribution plots for structural pro-
teins gp22 and gp29 were assigned from direct OD570nm
values, according to Reed et al.23
Protein localization in phage capsids in transmission
electron microscopy
Fifty microliters of phage preparations was deposited on
nickel formvar/carbon coated transmission electron micros-
copy (TEM) grids (400-mesh) and incubated for 1 min. Then,
the excess liquid was removed by using the side of a What-
man blotting paper, and the grids were blocked with 1% (w/v)
bovine serum albumin. Ammonium sulfate-precipitated an-
tibodies from phage-protein specific murine plasma samples
were then added, and the grids were incubated for 1 h. Sub-
sequently, the grids were extensively washed in PBS, and
1:50 diluted immunoconjugate gold-labeled secondary anti-
body (10 nm; Sigma) was deposited on the grids. The grids
were incubated for 15 min and then again extensively washed
in PBS, followed by distilled water. Finally, the samples were
stained with 2% uranyl acetate and were observed with a
Zeiss EM900 transmission electron microscope.
Ethics approval statement
All animal experiments were performed according to
EU Directive 2010/63/EU for animal experimentations and
were approved by the first Local Committee for Experiments
with the Use of Laboratory Animals, Wroclaw, Poland
(No. 64/2009). The authors followed the Animal Research:
Reporting of In Vivo Experiments guidelines.24
Results
Specific immune response to phages F8, LMA2,
and P1 in mice
Kinetics of specific immune response induction by phages
F8, LMA2, and DP1 (morphology by TEM: Supplementary
Fig. S2) was assessed in mice by identification of phage-
specific IgM and IgG in murine sera for an 80-day period.
Phages were injected IP as purified preparations 1010 pfu per
mouse on days 0, 20, and 55. All phages effectively induced
specific IgM and specific IgG; antibodies increased within the
first week after injection, reaching their maximum peaks
around days 5–20 (IgM) and 10–20 (IgG). Later, serum levels
of phage-specific antibodies slightly decreased, but they
remained markedly higher than those observed in control
(PBS-injected) mice.
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Differences between the investigated phages in IgG lev-
els (Fig. 1, IgG) may suggest differences in their overall
immunogenicity. Specifically, the highest enzyme-linked
immunosorbent assay (ELISA) signal was detected for phage
F8, followed by phage DP1, whereas phage LMA2 had the
lowest signal. The signal observed for LMA2 was also
weak when compared with other phages investigated to
date: T4 phage6 and staphylococcal phages A3R and 676Z
(Kaźmierczak et al., under assessment). This suggests that
LMA2 is a phage characterized by relatively lower immu-
nogenicity under the conditions studied.
Induction of specific antibodies in mice by structural
proteins gp22 and gp29
To assess the contribution of individual structural proteins
to the immunogenicity, we selected two important structural
proteins for recombinant expression and analysis, gp22 and
gp29. These proteins are highly conserved in F8, LMA2, and
DP1. Homological proteins in the related phage SN were
previously identified as head decorating (gp22) and tail
sheath forming (gp29) proteins.21,25 We confirmed this struc-
tural function and localization, by performing immuno-
microscopy on DP1, using gp22- and gp29-specific sera in
mice, developed by using recombinant highly purified pro-
teins gp22 and gp29 (Supplementary Fig. S3).
The immunogenicity of recombinant gp22 and gp29 as
structural elements of the phage virions was investigated in
murine sera from animals challenged with bacteriophages F8,
LMA2, or DP1 (Fig. 1). Relative IgG levels were compared
in ELISA with isolated recombinant proteins of all investi-
gated phages as bottom antigens (Fig. 2). Gp22 induced
marked levels of specific IgG in all phages, but gp29 induced
a markedly stronger response in animals treated with F8 or
DP1, but a weaker response in animals treated with the
LMA2 phage. This is consistent with the lower antibody level
observed for LMA2 in the analysis of the entire phage par-
ticles (Fig. 1). It suggests that weaker response to gp29
may be the reason for the lower reactivity of the sera with
the entire virion particle. Nevertheless, both proteins (gp22
and gp29) contribute significantly to the development of
phage-specific sera in mice. We also compared the neutral-
izing potential of specific anti-gp22 and anti-gp29 sera, but
no significant neutralizing activity could be observed in any
phage (data not shown).
F8, LMA2, and DP1 phage-specific sera in a healthy
human population without phage therapy
Humans are naturally exposed to phages that are com-
monly present in food and water, as these viruses constitute a
major part of the natural human virome.26,27 Antibodies that
result from continuous contact with phages are often called
natural antibodies. Here, we determine the frequency of
natural antibodies that are specific to F8, LMA2, and DP1
in healthy human volunteers who have not been subjected
to phage therapy (N = 55, the same collection of sera as pre-
viously used to assess immune response to T4 phage).6 Sera
were incubated with bacteriophages F8, LMA2, or DP1
(2 · 106 – 4 · 106 pfu/mL) to identify the neutralizing activity
of phage-specific antibodies. Neutralizing activity was found
as follows: 15% (8 out of 55) for phage F8, 11% (6 out of 55)
for phage LMA2, and 40% (22 out of 55) for phage DP1.
The differences between DP1 phage and F8 phage or
LMA2 phage were statistically significant (McNemar’s test,
p = 0.0005 and 0.0008, respectively); no significant dif-
ference between F8 and LMA2 phage was observed
( p = 0.7266). Inhibition of phage activity by positive sera,
although evident, was not strong: phage titer on average re-
mained in the same order of magnitude as controls (12% of
initial phage titer in F8 and 25% in LMA2 and DP1) (Fig. 3).
Interestingly, despite the fact that F8, LMA2, and DP1 pha-
ges are closely related and highly similar, the reactivity of
specific individuals’ sera was different between phages in
42% (23 out of 55) of studied individuals (Supplementary
Table S2). This demonstrates antigenic differences between
these three closely related phages, and it suggests their com-
plementary potential if used in human phage therapy.
Also, IgG fractions specific to our selected structural phage
proteins (gp22 and gp29) were assessed in the same collec-
tion of healthy humans’ sera. The levels of antibodies specific
to both investigated proteins were tested in sera previously
FIG. 1. Specific immune response to phages F8, LMA2,
DP1 in mice. Purified phages were injected IP, 1010 pfu per
mouse (N = 7), on days 0, 20, and 55 (arrows). Figure legend
is given as follows: F8-serum level of F8 phage-specific
antibodies in phage-challenged mice, F8 control-serum level
of F8 phage-specific antibodies in control mice injected with
PBS, LMA2-serum level of LMA2 phage-specific anti-
bodies in phage-challenged mice, LMA2 control-serum le-
vel of LMA2 phage-specific antibodies in control mice
injected with PBS, P1-serum level of P1 phage-specific
antibodies in phage-challenged mice, and P1 control-serum
level of P1 phage-specific antibodies in control mice in-
jected with PBS. This experiment was repeated three times,
and the exemplary result is presented. IP, intraperitoneally;
PBS, phosphate-buffered saline.
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FIG. 2. Individual immunogenicity of two capsid proteins: gp22 and gp29 in phages F8, LMA2, and DP1. Purified phages
were injected IP 1010 pfu per mouse (N = 7) on days 0, 20, and 55. Blood sera from these mice were tested for IgG antibodies
specific to structural proteins gp22 and gp29. Results are presented as OD by ELISA. Statistically significant differences
( p < 0.001 Kruskal–Wallis analysis of variance) between groups are indicated with asterisks. ELISA, enzyme-linked
immunosorbent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; OD, optical density.
FIG. 3. F8, LMA2, and DP1 phage-inhibitory effect of healthy humans’ sera; sera were collected from 55 healthy donors
never subjected to phage therapy, (A) frequency of phage-inhibitory effect in the investigated donors, (B) the strength of
phage inhibition by the investigated sera: average phage titer after incubation with positive and negative sera. Negative
sera—not inactivating phage (phage titer after incubation was within the range: mean value of the control –2 · standard
deviation); 8, 6, and 22 samples could be classified into this group in the case of F8, LMA2, and DP1, respectively. Positive
sera—inactivating the phage (phage titer after incubation was lower than the range of the negative samples); 47, 49, and 33
samples could be classified into this group in the case of F8, LMA2, and DP1, respectively. The control was calculated from
titers of the same phage preparation incubated with fetal bovine serum (N = 6).
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identified as ‘‘positive’’ (Fig. 3). They were compared by
ELISA with reverse cumulative plotting, but no significant
differences in population immunity to proteins gp22 and
gp29 could be detected (Fig. 4). Thus, no differences be-
tween these proteins’ contribution to PB1-like phages’ im-
munogenicity at the population level (that is: in healthy
human volunteers as representatives for the human popula-
tion) were detected, although specific antibodies for all
proteins were observed in the investigated population.
The relatively high cutoff values observed in the plots argue
that proteins gp22 and gp29 are not involved in the induction
of phage-neutralizing antibodies. Neutralization can proba-
bly be elicited by other virion proteins, most likely those
engaged in the process of phage-infecting bacteria; this issue
could be investigated further in the future, but remains de-
pendent on the availability of purified recombinant structural
proteins and corresponding sera for all virion-associated
proteins.
Anti-F8 phage antibodies and anti-phage protein
(gp22 and gp29) antibodies in patients subjected
to phage therapy
Among the investigated phages, F8 belongs to the group
of therapeutic phages used in the Phage Therapy Unit of
HIIET.20 Antibodies specific to structural proteins gp22
and gp29 were further investigated in patients treated for
Pseudomonas infections at the PTU HIIET (for description
of the patients see: Supplementary Table S3). In general, we
did not observe increased specific immune responses to the
F8 phage. First, the efficiency of plating phages before and
after phage therapy revealed no significant increase in phage-
neutralizing activity of patients’ sera (data not shown),
though only 11 patients were available for this study. These
patients were not injected with phage preparations, but
they were treated either orally or topically, which makes an
important limitation for comparisons to the animal model.
However, assessment of IgG fractions specific to proteins
gp22 and gp29 (in the same sera from patients undergoing
phage therapy) revealed no significant differences when
compared before and after phage therapy (Supplementary
Fig. S3).
Discussion
Consistent with other phages, bacteriophages F8, LMA2,
and DP1 can induce phage-specific antibodies.1–6,10,28 In
our animal model, these phages also display similar kinetics
of IgM and IgG induction as those of other bacteriophage
isolates (A3R, 676Z, T4)7,29 (Kaźmierczak et al., under as-
sessment). Since these observations are very similar for
taxonomically different phages, with different host bacteria,
the observed kinetics of immune responses to phages seems
to be universal and might also apply to other phages. At least
phages characterized with similar structure and chemical
composition (dsDNA, tailed) may share similar immunoge-
nicity and resulting kinetics of immune response to phages.
To date, variations in administration schedules and doses
levels have not yet been studied, but they could result in
differences in kinetics.
Among the investigated phages, LMA2 appears to be the
least immunogenic in our analyses (Fig. 1). Further, struc-
tural protein gp29 was less immunogenic in the LMA2 than
in the F8 and DP1 phage (Fig. 2), which offers an interesting
FIG. 4. Frequency of antibodies specific to F8, LMA2, and DP1 phage structural proteins gp22 and gp29 in the human
population. Serum samples (N = 55) were tested at 1:100 dilution in ELISA. Reverse cumulative distribution plots for
positive sera (Fig. 3) are presented, and cutoff values for negative sera (Fig. 3) are represented by vertical lines in each plot.
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consistency. Indeed, these data suggest that differences in
‘‘total immunogenicity’’ of PB1-like phages (response in-
duced by whole virions) may result from specific differences
in the ability of gp29 to induce specific IgG. Protein gp29
in LMA2 differs from its homologs in F8 and DP1 in only
two positions: Thr37/Pro and Ile67/Thr (F8 or DP1/
LMA2, respectively) (Supplementary Fig. S4). Reports on
immunogenicity of similar peptides are extremely scarce, but
one report from in silico models developed for eukaryotic
viruses suggested that threonine deletion might result in de-
creased immunogenicity of viral peptides.30 Thus, it is pos-
sible that substitution in the position 37 mediated observed
lower immunogenicity of the LMA2 phage in this model.
However, it should be noted that there is a limitation for
comparisons of phage immunogenicity (between phage iso-
lates) due to differences in phage adherence to detection
plates in ELISA31 Since specific testing by quantitative PCR
(qPCR) for very small quantities of PB1-like phages (like
those immobilized on plastic surfaces) has not been validated
yet, detailed comparison between F8, LMA2, and DP1 phage
is not available. As long as reference genes for qPCR in this
group of phages have not been revealed, unverified adherence
of the investigated phages to plates should be considered as
the study limitation. An overall (with whole phage virions)
assessment of how F8, LMA2, and DP1 can be detected by
ELISA was conducted by cross-reaction testing (Supple-
mentary Fig. S5) and it revealed no differences between these
three phages.
In the healthy human population, the lowest frequency of
phage-neutralizing antibodies (11%) was also observed for
LMA2. This frequency was slightly higher for F8 (15%) and
markedly higher for DP1 (40%) (Fig. 3). Despite the fact that
the investigated phages are highly similar, reactivity of a
particular human’s sera differed between phages in 42% of
individuals (23 people out of 55) (Supplementary Table S2).
This demonstrates antigenic differences between closely re-
lated phage strains, suggesting that in cases where specific
immune response hinders therapeutic use of phage, similar
phages have a complementary potential. Further, sera used
in this study were the same as those used in the identification
of Escherichia phage T4 neutralizing sera6 and staphylo-
coccal phages A3R and 676Z neutralizing sera (Kaźmierczak
et al., under assessment), for which neutralization frequen-
cies of 82% and about 35% were observed, respectively. This
demonstrates that pre-immunization of the human population
to phages is highly differentiated between phage isolates.
Probably, antibodies specific to phages that are common in
the environment and human gastrointestinal tracts (like T4)
are more frequent than those neutralizing other phages.
No significant differences were found in population im-
munity (specific IgG in healthy humans) to proteins gp22
and gp29 (Fig. 4). These proteins were selected for the study
due to their structural function and good exposition on
phage capsids, as previously demonstrated21,25 and con-
firmed herein for the DP1 phage (Supplementary Fig. S3).
Their contribution to the immunogenicity of PB1-like phages
at the population level seems to be of limited importance,
although specific antibodies (to these proteins) were observed
in the investigated population. Importantly, ‘‘positive’’ and
‘‘negative’’ human sera (Fig. 3) were determined by their
ability to neutralize the phages, whereas gp22- and gp-29
specific sera developed in mice did not affect the activity of
the investigated phages (data not shown). Further, relatively
high cutoff values were observed in the anti-gp22 and anti-
gp29 plots from healthy human populations (Fig. 4), which
means that a correlation between their occurrence and phage-
blocking activity of the sera was weak. This further indicates
that proteins gp22 and gp29 are not involved in the induc-
tion of phage-neutralizing antibodies. Neutralization might
probably be elicited by other virion proteins, or by their
combination. Such proteins must probably be directly in-
volved in the process of phage infection of bacteria, since
antibodies specific to gp29 do not affect phage infectivity.
Also, in patients treated for Pseudomonas infections with F8
phage (Phage Therapy Unit of HIIET), no significant increase
in the levels of gp22- and gp29-specific IgG was observed
(Supplementary Table S3). So far, no immunological data
on other (than F8) PB1-like phage used in phage therapy in
humans are available. For this reason, possible cross-
reactions and cross-neutralization cannot be fully excluded.
An important caveat here, which limits the comparison, is
also the difference in administration route, between the
therapeutic application (to humans) and model application
(to animals), as patients were treated orally. For this reason,
further investigation of other administration routes and
schedules should be considered one of the major directions in
immunological studies of these therapeutic phages.
Conclusion
Important structural phage proteins, present in virions in
many copies (e.g., tail sheath assembly), are potentially ca-
pable of inducing specific antibodies (as demonstrated in
mice), but they proved much less immunogenic in humans
when applied in the therapeutic schedule. In addition, in-
duced anti-gp22 and anti-gp29 antibodies had no direct neu-
tralizing effect on phage activity. In the future, other
structural proteins of PB1-like phages should to be investi-
gated, together with other schedules of immunization and
exposition to phages.
Overall, these observations contribute to our limited un-
derstanding of how specific immune response determines
phage bioavailability in animals and in humans. However,
the impact toward phage cocktail design and the individual
success rate of phage therapy applications may be directly
linked to these properties and should be incorporated as a key
parameter in clinical trial studies on phage therapy.
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